Andre Uddin
Stock Analyst at Research Capital
(4.72)
# 733
Out of 5,051 analysts
87
Total ratings
43.4%
Success rate
30%
Average return
Main Sectors:
Stocks Rated by Andre Uddin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: MDNA Medicenna Therapeutics Corp. | Reiterated: Buy | $3.75 → $1.60 | $0.44 | +267.82% | 9 | Jun 29, 2026 | |
| TSX: EDT Spectral Medical Inc. | Reiterated: Buy | $3.50 | $1.11 | +215.32% | 3 | May 31, 2026 | |
| TSXV: TLT Theralase Technologies Inc. | Reiterated: Buy | $0.70 | $0.18 | +300.00% | 7 | May 25, 2026 | |
| TSXV: COV Covalon Technologies Ltd. | Reiterated: Buy | $2.90 | $3.97 | -26.95% | 1 | May 22, 2026 | |
| NGEN NervGen Pharma | Reiterated: Buy | $5.5 | $1.73 | +217.92% | 4 | Apr 10, 2026 | |
| TSX: SVA Sernova Biotherapeutics Inc | Reiterated: Buy | $3.50 → $0.60 | $0.12 | n/a | 3 | Jun 19, 2025 | |
| TSX: GUD Knight Therapeutics Inc. | Upgraded: Buy | $6.50 → $7.50 | $10.83 | n/a | 11 | Mar 11, 2025 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Reiterated: Buy | $5.50 → $5.90 | $4.95 | n/a | 9 | Mar 26, 2024 | |
| ABILF Ability Inc. | Reiterated: Buy | $0.8 | $0.0001 | n/a | 1 | Aug 31, 2023 | |
| TSXV: BLU BluEnergies Ltd. | Reiterated: Buy | $11.10 → $20.48 | $2.49 | n/a | 11 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25.00 | $0.39 | n/a | 2 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4.65 → $1.50 | $13.65 | n/a | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.60 → $2.80 | $2.98 | n/a | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16.20 | $9.83 | n/a | 8 | Apr 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.02 | n/a | 7 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $16.55 | n/a | 4 | Oct 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $9.45 | n/a | 1 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.39 | n/a | 1 | May 17, 2017 |
Medicenna Therapeutics Corp.
Jun 29, 2026
Reiterated: Buy
Price Target: $3.75 → $1.60
Current: $0.44
Upside: +267.82%
Spectral Medical Inc.
May 31, 2026
Reiterated: Buy
Price Target: $3.50
Current: $1.11
Upside: +215.32%
Theralase Technologies Inc.
May 25, 2026
Reiterated: Buy
Price Target: $0.70
Current: $0.18
Upside: +300.00%
Covalon Technologies Ltd.
May 22, 2026
Reiterated: Buy
Price Target: $2.90
Current: $3.97
Upside: -26.95%
NervGen Pharma
Apr 10, 2026
Reiterated: Buy
Price Target: $5.5
Current: $1.73
Upside: +217.92%
Sernova Biotherapeutics Inc
Jun 19, 2025
Reiterated: Buy
Price Target: $3.50 → $0.60
Current: $0.12
Upside: n/a
Knight Therapeutics Inc.
Mar 11, 2025
Upgraded: Buy
Price Target: $6.50 → $7.50
Current: $10.83
Upside: n/a
Medexus Pharmaceuticals Inc.
Mar 26, 2024
Reiterated: Buy
Price Target: $5.50 → $5.90
Current: $4.95
Upside: n/a
Ability Inc.
Aug 31, 2023
Reiterated: Buy
Price Target: $0.8
Current: $0.0001
Upside: n/a
BluEnergies Ltd.
Feb 24, 2022
Reiterated: Buy
Price Target: $11.10 → $20.48
Current: $2.49
Upside: n/a
May 10, 2021
Reiterated: Buy
Price Target: $25.00
Current: $0.39
Upside: n/a
May 8, 2020
Reiterated: Buy
Price Target: $4.65 → $1.50
Current: $13.65
Upside: n/a
Apr 16, 2020
Reiterated: Hold
Price Target: $7.60 → $2.80
Current: $2.98
Upside: n/a
Apr 7, 2020
Downgraded: Hold
Price Target: $16.20
Current: $9.83
Upside: n/a
Jan 13, 2020
Reiterated: Buy
Price Target: n/a
Current: $2.02
Upside: n/a
Oct 31, 2019
Reiterated: Buy
Price Target: $10
Current: $16.55
Upside: n/a
Nov 13, 2017
Rated: Buy
Price Target: n/a
Current: $9.45
Upside: n/a
May 17, 2017
Reiterated: Buy
Price Target: $15
Current: $2.39
Upside: n/a